Shionogi Of Japan, GSK Of U.K. Report Good Results From HIV/AIDS Drug
This article was originally published in PharmAsia News
Japan's Shionogi reports strong encouragement from Phase II trials for its drug to treat HIV/AIDS. Shionogi is testing the drug as part of a joint development deal with GlaxoSmithKline of the United Kingdom. Their study indicated the S/GSL1349572 drug lowered the virus to levels that could not be detected in 70 percent of the participants. After 10 days, none of the South Africa patients displayed drug resistance, the study said. The drug relies on blocking the integrase enzyme. (Click here for more
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.